Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark (Conformité Européenne) for the Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with diabetes in Europe age two years and older, including pregnant women.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220309005998/en/
With Dexcom G7, real-time glucose readings are sent automatically to a compatible display device. (Photo: Business Wire)
Dexcom G7 offers a better way to help users gain greater control of their diabetes, so that they can manage it more confidently each day. Its low-profile, all-in-one wearable warms up faster than any other CGM on the market,* sending real-time glucose readings automatically to a compatible smart device‡ or receiver, no fingersticks required.† Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels and help users spend more time in range.§,2 Industry-leading remote monitoring and reporting capabilities also allow users to stay connected with their loved ones and care teams anytime, anywhere.||
“Today marks an incredible milestone for our company and for people with diabetes in Europe,” said Kevin Sayer, chairman, president and CEO of Dexcom. “This all-new platform offers an incredibly powerful CGM that is simple to use, providing our users with insightful glucose data on one screen that helps them spend less time managing diabetes and more time doing the things they love. Dexcom G7 takes everything people love about G6 and makes it even better.”
New features with Dexcom G7:
Dexcom G6 features included with Dexcom G7:
Dexcom is also working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible.
“Over the past 20 years, Dexcom has been one of the leaders and pioneers in advancing real-time CGM technology,” said Professor Partha S. Kar, OBE, national specialty advisor, Diabetes at NHS England and consultant endocrinologist at Portsmouth Hospitals NHS Trust. “With enhanced features and added simplicity, Dexcom G7 will hopefully make diabetes management easier for both patients and their healthcare providers, something that is especially important as we see more and more evidence of the benefits of CGM in broader populations of those living with diabetes.”
Dexcom expects to initiate a launch of Dexcom G7 in Europe in the next several weeks. The company also plans to introduce an updated CGM algorithm in 2022, driving the next step forward in CGM sensor performance.
Visit Dexcom.com and get started with Dexcom G6 today to experience the benefits of CGM now. To learn more about Dexcom G7 and for additional information about when it will be available in Europe, visit Dexcom.com/G7.
Dexcom submitted a comprehensive 510(k) pre-market notification to the U.S. Food and Drug Administration for regulatory review of the Dexcom G7 CGM System in accordance with the iCGM Special Controls in Q4 2021.††
About DexCom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including statements with respect to timing of the G7 launch in Europe, updates to its CGM algorithm and impacts to diabetes management. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Dexcom, deal with future events, are subject to various risks and uncertainties, including risks and uncertainties relating to our development, preparation, and potential future submission of a 510(k) application for G7 to the US FDA and the potential timing or results of regulatory review of such an application, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in Dexcom’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on October 28, 2021. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.
*Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
†If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡To view a list of compatible smart devices, visit dexcom.com/compatibility
§Results obtained with a prior generation Dexcom CGM System.
||Separate Dexcom Follow app and internet connection required. Internet connectivity required for data sharing. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions.
¶Compared to a prior generation Dexcom CGM System.
#Healthcare providers can register for Dexcom Clarity at clarity.dexcom.com/professional/ registration.
**An internet connection is required for patients to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity.
††Pending 510(k) clearance -- Not available for sale in the U.S.
1 Dexcom, data on file, 2021
2 Beck RW, et al. JAMA. 2017;317(4):371-378.
3 Welsh JB, et al. Diabetes Technol Ther. 2019;21(3):128-132.
4 Dexcom G7 User Guide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canadian Tire Bank Selects Temenos Open Platform to Gain Best-In-Class Digital Banking Capabilities18.5.2022 09:00:00 CEST | Press release
Temenos (SIX: TEMN) today announced that Canadian Tire Bank (CTB), the financial arm of Canadian Tire Corporation (CTC) – one of the largest Canadian retail companies – has selected Temenos open platform for composable banking to replace its legacy systems. Temenos will help power Canadian Tire Bank’s growth by delivering faster to market and richer digital experiences, boosting customer engagement and bottom-line revenue. The new banking platform is part of CTC’s Better Connected strategic growth plan to invest in its omnichannel customer experience. Temenos open platform will help Canadian Tire Bank (CTB) drive its digital-first strategy to enhance customer acquisition, loyalty and engagement. Canadian Tire Bank is one of the largest card issuers in Canada, with more than 2 million customers, over $6B in receivables and was recently ranked second in JD Power’s Canada Credit Card Satisfaction Study. With CTB focused on launching a new set of digital-only offerings, Temenos will help e
Temenos Delivers Digital Banking Solutions on AWS18.5.2022 08:30:00 CEST | Press release
Temenos (SIX: TEMN) and Amazon Web Services (AWS), have extended their global relationship to run Temenos onboarding and origination solutions on AWS. The technology collaboration aims to allow all retail and commercial banks - incumbents and challengers - to provide digital onboarding and origination solutions with higher performance, scalability, and security. It will give banks greater agility while reducing time to market and improve cost efficiency. The two companies will go-to-market with solutions for retail, business, corporate and private banking, and wealth. This multi-year agreement aims to offer the full suite of Temenos banking solutions on AWS as-a-service. Temenos and AWS started working together in 2019 to integrate Temenos open platform onto AWS and have demonstrated success with joint banking customers since then. With Temenos digital banking solutions, Temenos and AWS are making it easier for banks to access the technology they need to meet rising customer expectatio
Collecting Sensitive Data Without User Consent: 24 Leading Online Pharmacies From Nordic Countries Fail GDPR Requirements – Usercentrics Reports18.5.2022 08:01:00 CEST | Press release
Analysis by Usercentrics shows: Over 80% of scanned domains from Denmark, Sweden and Norway are not GDPR compliant, setting at least one non-necessary cookie without user consent. Sweden ranks highest with an average of 26 non-necessary cookies set. In total 89% of the most popular online pharmacies in the EU do not meet GDPR requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517006345/en/ Lack of Data Protection on EU Pharma Webshops: The majority of websites do not operate in a privacy-compliant manner - analysis by Usercentrics shows. (Graphic: Business Wire) Pharmacy webshops constantly process personal data of their visitors, while selling privacy-sensitive products such as antidepressants, diabetes medicines or addiction treatments. Usercentrics scanned the 150 most-used pharmacy webstores in the EU, analyzing the extent to which website operators are complying with the General Data Protection Regulation (
Banks Shift to Eco-friendly Solutions Supported by Innovative Thales Cards, Certified Sustainable by Mastercard18.5.2022 08:00:00 CEST | Press release
The amount of plastic used to produce payment cards every year is equivalent to the weight of 125 Statues of Liberty1. With environmental challenges now a growing, global concern, Thales, the leader in high tech security, has developed solutions for a greener world, recently certified by Mastercard’s Sustainable Card Program. To date, Thales has deployed 30 million eco-friendly payment cards for banks and card issuers that address consumer concerns without compromising the user experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005012/en/ (Photo: Thales) All eco-friendly cards offered by Thales are made with innovative and sustainable components. For example, one solution is a card made from 85% PLA (polylactic acid), which is produced from corn. Another innovative approach reduces the amount of new plastic while fighting sea pollution, with a card made of Ocean Plastic® collected by Parley for the Oceans. This
Anterra Capital: Pandemic and Food Price Inflation Fuel Investor Interest to Accelerate Transformation of the Food and Ag Sector18.5.2022 07:00:00 CEST | Press release
A crushing pandemic and, more recently, the Ukraine war have convinced investors more than ever that the world needs to radically change how it produces, distributes and consumes food, says Adam Anders, managing partner of the international food and agriculture specialist venture capital firm Anterra Capital (“Anterra”). Anders: “The pandemic highlighted the fragility and adverse health impacts of our current food system: soaring prices, empty shelves in stores; the fact that unhealthy diets are a major risk factor for getting Covid; that the way we treat farm animals could trigger the next pandemic. Post our final closing, the devastating impact of the Ukraine War on the global food supply has increased the awareness among investors even further. This, plus our focus on deploying proven biotech and digital solutions to shake up the lagging Food and Ag-sector, go a long way in explaining the higher than expected interest in our second fund.” Anterra is proud to announce the closing of